Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ST6GAL1 | P15907 | 10/20 | 0.46 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.44 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.43 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | CD22 | P20273 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14027764 | 1.00 | ST6GAL1 (0.46) | ST6GAL1P2RY2P2RY4P2RY6TSHR | |
| SCHEMBL18494422 | 0.95 | ST6GAL1 (0.47) | ST6GAL1P2RY2P2RY4P2RY6TSHR | |
| SCHEMBL14414545 | 0.94 | ST6GAL1 (0.40) | ST6GAL1P2RY2P2RY4P2RY6CD22 | |
| SCHEMBL10187590 | 0.94 | ST6GAL1 (0.45) | ST6GAL1P2RY2P2RY4P2RY6CD22 | |
| SCHEMBL10044124 | 0.94 | ST6GAL1 (0.46) | ST6GAL1P2RY2P2RY4P2RY6TSHR | |
| SCHEMBL29397564 | 0.94 | ST6GAL1 (0.48) | ST6GAL1P2RY2P2RY4P2RY6CD22 | |
| SCHEMBL29397212 | 0.94 | ST6GAL1 (0.48) | ST6GAL1P2RY2P2RY4P2RY6CD22 | |
| SCHEMBL18495200 | 0.93 | ST6GAL1 (0.47) | ST6GAL1P2RY2P2RY4P2RY6TSHR | |
| SCHEMBL12495844 | 0.93 | ST6GAL1 (0.47) | ST6GAL1P2RY2P2RY4P2RY6TSHR | |
| SCHEMBL16093276 | 0.93 | ST6GAL1 (0.47) | ST6GAL1P2RY2P2RY4P2RY6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170136104-A1 | GLYCOPEGYLATED FACTOR IX | NOVO NORDISK AS (DK) | 2017-05-18 | — | — | US | disclosed |
| US-20170007712-A1 | GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS | NOVO NORDISK A/S (DK) | 2017-01-12 | — | — | US | disclosed |
| US-20160361427-A1 | Glycopegylated Factor IX | NOVO NORDISK AS (DK) | 2016-12-15 | — | — | US | disclosed |
| US-20160200795-A1 | FACTOR VIII: REMODELING AND GLYCOCONJUGATION OF FACTOR VIII | NOVO NORDISK A/S (DK) | 2016-07-14 | — | — | US | disclosed |
| US-20160193353-A1 | FACTOR VIII: REMODELING AND GLYCOCONJUGATION OF FACTOR VIII | NOVO NORDISK A/S (DK) | 2016-07-07 | — | — | US | disclosed |
| US-20160184412-A1 | Glycopegylated Factor IX | NOVO NORDISK AS (DK) | 2016-06-30 | — | — | US | disclosed |
| US-20160158319-A1 | REMODELING AND GLYCOPEGYLATION OF FIBROBLAST GROWTH FACTOR (FGF) | NOVO NORDISK A/S (DK) | 2016-06-09 | — | — | US | disclosed |
| US-20150343080-A1 | GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS | NOVO NORDISK AS (DK) | 2015-12-03 | — | — | US | disclosed |
| US-9200049-B2 | Remodeling and glycopegylation of fibroblast growth factor (FGF) | NOVO NORDISK A/S (DK) | 2015-12-01 | — | — | US | disclosed |
| US-9187532-B2 | Glycosylation of peptides via O-linked glycosylation sequences | NOVO NORDISK A/S (DK) | 2015-11-17 | — | — | US | disclosed |
| US-7276475-B2 | Remodeling and glycoconjugation of peptides | NEOSE TECHNOLOGIES, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| US-7265084-B2 | Glycopegylation methods and proteins/peptides produced by the methods | NEOSE TECHNOLOGIES, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-7226903-B2 | Interferon beta: remodeling and glycoconjugation of interferon beta | NEOSE TECHNOLOGIES, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-20070059275-A1 | Antibody toxin conjugates | NOVO NORDISK A/S (DK) | 2007-03-15 | — | — | US | disclosed |
| US-20070042458-A1 | ERYTHROPOIETIN: REMODELING AND GLYCOCONJUGATION OF ERYTHROPOIETIN | NEOSE TECHNOLOGIES, INC. | 2007-02-22 | — | — | US | disclosed |
| US-7179617-B2 | Forming a convalent conjugate of a Factor IX peptide, removing X2 or a saccharyl subunit thereof from peptide forming a truncated glycan; contacting truncated glycan with glycosyltransferase and modified sugar donor under conditions suitable for glycosyltransferase to transfer a modified sugar moiety | NEOSE TECHNOLOGIES, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-7173003-B2 | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF | NEOSE TECHNOLOGIES, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-20070026485-A1 | Glycopegylation methods and proteins/peptides produced by the methods | NEOSE TECHNOLOGIES, INC. (US) | 2007-02-01 | — | — | US | disclosed |
| US-20070027068-A1 | Erythropoietin: remodeling and glycoconjugation of erythropoietin | NOVO NORDISK A/S (DK) | 2007-02-01 | — | — | US | disclosed |
| US-7157277-B2 | Factor VIII remodeling and glycoconjugation of Factor VIII | NEOSE TECHNOLOGIES, INC. (US) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158319-A1 | REMODELING AND GLYCOPEGYLATION OF FIBROBLAST GROWTH FACTOR (FGF) | FGF2, FGF1, FGFR1 | ST6GAL1 48/4885P2RY2 3944/4885P2RY4 3930/4885 |
| US-20160200795-A1 | FACTOR VIII: REMODELING AND GLYCOCONJUGATION OF FACTOR VIII | F13B, F8, F13A1 | ST6GAL1 30/4885P2RY2 4558/4885P2RY4 4406/4885 |
| US-20070027068-A1 | Erythropoietin: remodeling and glycoconjugation of erythropoietin | EPOR, HBG2, HAMP | ST6GAL1 410/4885P2RY2 4650/4885P2RY4 4645/4885 |
| US-20160193353-A1 | FACTOR VIII: REMODELING AND GLYCOCONJUGATION OF FACTOR VIII | F13B, F8, F13A1 | ST6GAL1 30/4885P2RY2 4558/4885P2RY4 4406/4885 |
| US-20160361427-A1 | Glycopegylated Factor IX | F9, F13A1, F13B | ST6GAL1 22/4885P2RY2 4815/4885P2RY4 4805/4885 |
| US-20070026485-A1 | Glycopegylation methods and proteins/peptides produced by the methods | PTMS, ANPEP, NGLY1 | ST6GAL1 57/4885P2RY2 4763/4885P2RY4 4768/4885 |
| US-20170136104-A1 | GLYCOPEGYLATED FACTOR IX | F9, F13A1, F13B | ST6GAL1 22/4885P2RY2 4815/4885P2RY4 4805/4885 |
| US-20170007712-A1 | GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS | PTMS, ANPEP, NGLY1 | ST6GAL1 57/4885P2RY2 4763/4885P2RY4 4768/4885 |
| US-20070042458-A1 | ERYTHROPOIETIN: REMODELING AND GLYCOCONJUGATION OF ERYTHROPOIETIN | EPOR, HBG2, HAMP | ST6GAL1 410/4885P2RY2 4650/4885P2RY4 4645/4885 |
| US-20160184412-A1 | Glycopegylated Factor IX | F9, F13A1, F13B | ST6GAL1 22/4885P2RY2 4817/4885P2RY4 4809/4885 |
| US-20150343080-A1 | GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS | PTMS, ANPEP, NGLY1 | ST6GAL1 57/4885P2RY2 4763/4885P2RY4 4768/4885 |
| US-20070059275-A1 | Antibody toxin conjugates | CD47, ANTXR2, STT3A | ST6GAL1 9/4885P2RY2 3238/4885P2RY4 3099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.